现有的证据的审查维拉佐酮在重度抑郁症。

文章的细节

引用

复制到剪贴板

王SM,汉族C,李SJ, Patkar AA, Masand PS, Pae铜

现有的证据的审查维拉佐酮在重度抑郁症。

Int J精神病学Pract。2013年8月,17 (3):160 - 9。doi: 10.3109 / 13651501.2013.794245。2013年5月29日Epub。

PubMed ID

23578403 (在PubMed

]

文摘

目的:本文是通知医生目前数据维拉佐酮治疗重度抑郁症患者(MDD),关注其微分作用机理和扩展临床效用。方法:进行数据搜索2012年6月必威国际app使用PubMed / MEDLINE /相关临床试验数据库的关键术语“维拉佐酮”或“维拉佐酮”。RESULTS: The efficacy, safety, and tolerability of vilazodone have been demonstrated in two pivotal 8-week, randomized, double-blinded, placebo-controlled studies. Certain pharmacological characteristics of vilazodone were observed, including early onset of action, fewer sexual side effects, the absence of known cardiac toxicity, and minimal effect on weight gain, that may provide potential clinical advantages compared with currently available antidepressants. However, such possibilities should be replicated and confirmed in more well-designed and adequately powered clinical trials. Vilazodone requires dose titration up to 2 weeks to reach a target dose of 40 mg/d due to high rate of gastrointestinal side effects. No direct comparative studies with other antidepressants are currently available to confirm the aforementioned potential clinical utility. CONCLUSION: Vilazodone is a newer antidepressant possessing different action mechanisms compared to currently available antidepressants but whether it has superiority to other class of antidepressants in terms of efficacy and safety should still warrant further evaluation through more well-controlled and direct comparison clinical trials.

DrugBank数据引用了这篇文章

药物

维拉佐酮